JP2011231095A - Agent for ameliorating type-2 diabetes, and food and beverage containing the same - Google Patents
Agent for ameliorating type-2 diabetes, and food and beverage containing the same Download PDFInfo
- Publication number
- JP2011231095A JP2011231095A JP2010189716A JP2010189716A JP2011231095A JP 2011231095 A JP2011231095 A JP 2011231095A JP 2010189716 A JP2010189716 A JP 2010189716A JP 2010189716 A JP2010189716 A JP 2010189716A JP 2011231095 A JP2011231095 A JP 2011231095A
- Authority
- JP
- Japan
- Prior art keywords
- wax
- diabetes
- type
- test
- feed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 48
- 235000013305 food Nutrition 0.000 title claims description 18
- 235000013361 beverage Nutrition 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 41
- CGNVIRPGBUXJES-UHFFFAOYSA-N triacontanal Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC=O CGNVIRPGBUXJES-UHFFFAOYSA-N 0.000 claims description 21
- LVXORIXZNUNHGQ-UHFFFAOYSA-N octacosanal Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC=O LVXORIXZNUNHGQ-UHFFFAOYSA-N 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 8
- 244000241838 Lycium barbarum Species 0.000 claims description 2
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 2
- 235000015468 Lycium chinense Nutrition 0.000 claims description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 34
- 239000008280 blood Substances 0.000 abstract description 21
- 210000004369 blood Anatomy 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 17
- 102000004877 Insulin Human genes 0.000 abstract description 17
- 108090001061 Insulin Proteins 0.000 abstract description 17
- 239000008103 glucose Substances 0.000 abstract description 17
- 229940125396 insulin Drugs 0.000 abstract description 17
- 229930014626 natural product Natural products 0.000 abstract description 12
- 102000011690 Adiponectin Human genes 0.000 abstract description 7
- 108010076365 Adiponectin Proteins 0.000 abstract description 7
- 241000196324 Embryophyta Species 0.000 abstract description 7
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 5
- 102000007156 Resistin Human genes 0.000 abstract description 5
- 108010047909 Resistin Proteins 0.000 abstract description 5
- 229960001109 policosanol Drugs 0.000 abstract description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 abstract description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical class C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 abstract description 2
- 102000014777 Adipokines Human genes 0.000 abstract description 2
- 108010078606 Adipokines Proteins 0.000 abstract description 2
- 244000046109 Sorghum vulgare var. nervosum Species 0.000 abstract 2
- 239000000478 adipokine Substances 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 239000001993 wax Substances 0.000 description 88
- 238000012360 testing method Methods 0.000 description 33
- 240000000111 Saccharum officinarum Species 0.000 description 21
- 235000007201 Saccharum officinarum Nutrition 0.000 description 21
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 21
- 240000008067 Cucumis sativus Species 0.000 description 20
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 20
- 244000062793 Sorghum vulgare Species 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 15
- 238000009395 breeding Methods 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000002615 epidermis Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 230000001488 breeding effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000003549 soybean oil Substances 0.000 description 6
- 235000012424 soybean oil Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- -1 saturated aliphatic aldehyde Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000021195 test diet Nutrition 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 244000060011 Cocos nucifera Species 0.000 description 3
- 235000013162 Cocos nucifera Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229960002666 1-octacosanol Drugs 0.000 description 2
- 241000209134 Arundinaria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000190633 Cordyceps Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000138286 Sorghum saccharatum Species 0.000 description 2
- 238000000944 Soxhlet extraction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 235000015505 Sorghum bicolor subsp. bicolor Nutrition 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、天然産物であるコウリャンより抽出・分離されたワックス混合物を有効成分とするインスリン非依存性の2型糖尿病の改善剤及びそれを含有する飲食物に関する。 The present invention relates to an insulin-independent type 2 diabetes mellitus-improving agent comprising as an active ingredient a wax mixture extracted and separated from a natural product, cuolian, and a food and drink containing the same.
糖尿病は、上昇した血液中の糖分を正常レベルに戻す能力(耐糖能)が十分には機能しない病気であり、この耐糖能が低下するメカニズムによって1型糖尿病と2型糖尿病に大別される。
Diabetes mellitus is a disease in which the ability to return the increased sugar content in blood to a normal level (glucose tolerance) does not sufficiently function, and is roughly classified into
1型糖尿病は、インスリン依存型糖尿病ともいい、遺伝的な要素が強く、血糖を下げるホルモンであるインスリンを分泌している膵臓ランゲルハンス島のβ細胞が免疫異常によって破壊されるため、体内のインスリン濃度が極端に低下して血中の糖濃度が異常に増加する病気である。
一方、2型糖尿病は、インスリン非依存型糖尿病ともいい、肥満などの生活習慣病の原因から肝臓や筋肉などの細胞がインスリン作用に対して感受性の低下を引き起こすことが主な原因であり、この結果、血中のインスリン濃度および糖濃度が異常に増加する病気である。この2型糖尿病は、我が国の糖尿病全体の約95%以上を占めると言われている。 On the other hand, type 2 diabetes is also referred to as non-insulin dependent diabetes mellitus, and it is mainly caused by cells such as liver and muscle that cause decreased sensitivity to insulin action due to lifestyle-related diseases such as obesity. As a result, the blood insulin concentration and sugar concentration are abnormally increased. This type 2 diabetes is said to account for about 95% or more of all diabetes in Japan.
2型糖尿病の一般的な改善方法は、まず食事療法・運動療法から行い、症状が軽減しない場合には投薬による治療が行われる。2型糖尿病患者向けの投薬治療としては、既に数多くの方法が提案されており、例えば、肝糖新生抑制作用のグアナイド剤、末梢インスリン感受性改善作用のチアゾリジン系インスリン感受性改善剤、インスリン分泌刺激作用のスルフォニル尿素酸等の投薬療法が知られている。 A general method for improving type 2 diabetes is to start with diet therapy / exercise therapy, and if the symptoms are not alleviated, treatment with medication is performed. Numerous methods have already been proposed as medications for patients with type 2 diabetes. For example, guanide agents that suppress hepatic gluconeogenesis, thiazolidine-based insulin sensitivity improvers that improve peripheral insulin sensitivity, and insulin secretion stimulating effects. Medication therapies such as sulfonylurea acid are known.
一方、近年、重篤な副作用を伴わない天然物由来の分離成分(ワックス等)の生理活性効果がとくに注目され、現在までに有効成分の採取方法ならびに有効成分による糖尿病に対する改善の試みが以下のように数多く開示されている。 On the other hand, in recent years, the physiologically active effects of separated components derived from natural products (wax, etc.) without serious side effects have attracted particular attention. To date, methods for collecting active ingredients and attempts to improve diabetes with active ingredients are as follows. As many as disclosed.
(1)甘蔗(サトウキビ)茎部の表皮部分を剃刀あるいはピーラーで削り落して、有機溶媒を用いて加温状態下で抽出する方法の提案(特許文献1および2)
(2)甘蔗糖蜜などに含有されるケーンワックスを低級アルコールにて効率よく抽出し、分離回収する方法の提案(特許文献3)
(3)サトウキビ等の天然産物から得られるポリコサノールを含む抽出生成物の糖尿病性末梢神経障害の治療への応用の提案(特許文献4)
(4)トウモロコシのナンバの毛および冬虫夏草菌糸体の熱水抽出物が1型糖尿病ラットの血糖値を降下させる作用の開示(特許文献5)
(1) Proposal of a method of shaving off the skin part of a sugar cane stem with a razor or a peeler and extracting it under a heated condition using an organic solvent (
(2) Proposal of a method for efficiently extracting and separating and recovering cane wax contained in sugarcane molasses with lower alcohol (Patent Document 3)
(3) Proposal of application of an extract containing polycosanol obtained from natural products such as sugarcane to the treatment of diabetic peripheral neuropathy (Patent Document 4)
(4) Disclosure of action of hot water extract of corn number hair and cordyceps mycelium to lower blood glucose level of
さらに、とくに2型糖尿病の改善については、以下のような試みが開示されている。
(5)サトウキビ等の天然産物から抽出・分離した高級飽和脂肪族アルコールを有効成分とする2型糖尿病改善剤ならびに2型糖尿病改善食品の提案(特許文献6)
(6)サトウキビ等の天然産物から抽出・分離したポリコサノールと特定の薬理作用について知られている特定の物質との組合せの2型糖尿病およびインスリン抵抗性に対する有効性の開示(特許文献7)
Furthermore, the following attempts have been disclosed for improving type 2 diabetes.
(5) Proposal of type 2 diabetes improving agent and type 2 diabetes improving food containing higher saturated fatty alcohol extracted and separated from natural products such as sugarcane as active ingredients (Patent Document 6)
(6) Disclosure of effectiveness of combination of policosanol extracted / separated from natural products such as sugarcane and specific substances known for specific pharmacological action on type 2 diabetes and insulin resistance (Patent Document 7)
これらの試みでは、いずれも、甘蔗(サトウキビ)、トウモロコシ、その他の植物あるいは動物に由来する分離・抽出成分であるワックスあるいは高級飽和脂肪族アルコール(ポリコサノール)が用いられている。 In any of these attempts, sugar or higher saturated aliphatic alcohol (polycosanol), which is a separation / extraction component derived from sugar cane, corn, other plants or animals, is used.
また、前記特許文献1〜3では、サトウキビからの有効成分の抽出・分離方法あるいは抗脂血症や骨粗鬆症改善を試みてはいるが、2型糖尿病の改善効果については何ら言及されていない。また、前記特許文献4および5では、サトウキビ、トウモロコシのナンバの毛や冬虫夏草菌糸体の熱水抽出物についての生理活性効果を提案しているが、同様に2型糖尿病の改善効果については何ら言及されていない。 Moreover, although the said patent documents 1-3 are trying the extraction / separation method of the active ingredient from sugarcane, or antilipidemia and osteoporosis improvement, they do not mention at all about the improvement effect of type 2 diabetes. In addition, Patent Documents 4 and 5 propose physiologically active effects on sugarcane, corn numb hair, and hot water extract of Cordyceps mycelium, but there is no mention of any improvement effect on type 2 diabetes. It has not been.
一方、前記特許文献6および7ではサトウキビ等の天然産物から抽出・分離した高級飽和脂肪族アルコール(ポリコサノール)の2型糖尿病の改善効果を開示しているが、本発明の天然産物原料であるコウリャンについては何ら言及されていない。 On the other hand, Patent Documents 6 and 7 disclose the improvement effect of type 2 diabetes of higher saturated fatty alcohol (polycosanol) extracted and separated from natural products such as sugarcane. There is no mention about.
したがって、現在までに天然産物原料の中で、とくにコウリャンに着目した試みは一切なく、しかもコウリャンより抽出・分離された特定組成のワックス混合物が、2型糖尿病において血糖値あるいは血中インスリン濃度に対して優れた低下作用を有しかつアディポネクチン産生量を増加するとする先行技術はこれまでに全く見当らない。 Therefore, no attempt has been made so far to focus on colouran among the natural product raw materials, and a wax mixture of a specific composition extracted and separated from colouran has not been able to control blood sugar levels or blood insulin levels in type 2 diabetes. Thus far, no prior art has been found that has an excellent lowering effect and increases adiponectin production.
前記のごとく、2型糖尿病改善に対して天然物由来の成分を利用する幾つかの試みがなされているものの、十分な効果を発現する有効な技術は未だ提案されていない。従って、本発明は副作用の少ない天然物由来の成分により2型糖尿病を十分改善できる技術を提供することを課題とする。 As described above, although some attempts have been made to use components derived from natural products for improving type 2 diabetes, an effective technique that exhibits a sufficient effect has not yet been proposed. Therefore, an object of the present invention is to provide a technique capable of sufficiently improving type 2 diabetes with a component derived from a natural product with few side effects.
本発明者らは、前記の問題点に鑑み鋭意検討した結果、コウリャンより抽出・分離されたワックス混合物が、従来試みられていたコウリャン以外の植物あるいは動物に由来する分離成分であるワックスあるいは高級飽和脂肪族アルコール(ポリコサノール)に比べた場合、2型糖尿病マウスの血糖値および血漿中のインスリン濃度を効果的に著しく低下させ、かつアディポネクチン濃度を増加する優れた生理活性効果を有することを見出して本発明を完成するに至った。 As a result of intensive studies in view of the above problems, the present inventors have found that a wax mixture extracted and separated from cucumber is a wax or higher-saturation that has been conventionally attempted as a separation component derived from plants or animals other than cucumber. Compared with fatty alcohol (policosanol), this book has found that it has an excellent bioactivity effect that effectively remarkably lowers blood glucose level and plasma insulin concentration of type 2 diabetic mice and increases adiponectin concentration The invention has been completed.
すなわち本発明は、
(1)コウリャンより抽出・分離されたワックス混合物を有効成分とする2型糖尿病改善剤、
(2)ワックス混合物が、オクタコサナールおよびトリアコンタナールを主成分とする(1)記載の2型糖尿病改善剤、
(3)コウリャンが、コウリャンの表皮であることを特徴とする(1)記載の2型糖尿病改善剤、
(4)(1)、(2)又は(3)記載の2型糖尿病改善剤を含有する2型糖尿病改善飲食物
に関するものである。
That is, the present invention
(1) a type 2 diabetes mellitus ameliorating agent comprising a wax mixture extracted and separated from cucumber as an active ingredient,
(2) The type 2 diabetes-improving agent according to (1), wherein the wax mixture is mainly composed of octacosanal and triacontanal,
(3) The type 2 diabetes mellitus improving agent according to (1), wherein the sorghum is a sorghum epidermis,
(4) The present invention relates to a type 2 diabetes-improving food or drink containing the type 2 diabetes improving agent according to (1), (2) or (3).
本明細書は本願の優先権の基礎である日本国特許出願2009-233649号、2010-089463号、の明細書および/または図面に記載される内容を包含する。 This specification includes the contents described in the specification and / or drawings of Japanese Patent Applications Nos. 2009-233649 and 2010-089463, which are the basis of the priority of the present application.
本発明によれば、副作用の少ない天然物由来の成分により、2型糖尿病の病状が十分に改善される。 According to the present invention, the condition of type 2 diabetes is sufficiently improved by a component derived from a natural product with few side effects.
(1)本発明に用いる天然原料
本発明の原料であるコウリャンは、現代中国名が高粱(こうりゃん、カオリャン)であり、モロコシ、タカキビ(高黍)、また地方によりモロコシキビ、トウキビ、ソルガムとも呼ばれる、イネ科モロコシ属の一年草の植物・穀物である。熱帯、亜熱帯の作物で乾燥に強く、米、コムギなどが育たない地域でも成長し、主にアフリカ・中央アメリカ・東南アジアで食用に栽培される。草丈は、野生種でおおむね3メートルに達するが、栽培用品種では1.5メートル程度のものが多い。葉も長さ1メートル以上で幅10センチメートル程度になり、茎は太さ3センチメートル程度で芯の詰まったものとなっている。
(1) Natural raw material used in the present invention Koryang, which is the raw material of the present invention, has a modern Chinese name of Goryang, Kaorian, and is also called sorghum, cricket, or sorghum, sugarcane, sorghum, depending on the region. It is an annual plant and grain of the genus Sorghum. It is a tropical and subtropical crop that is resistant to drying and grows in areas where rice and wheat do not grow, and is cultivated for food mainly in Africa, Central America and Southeast Asia. The plant height is about 3 meters for wild species, but most of the cultivars are about 1.5 meters. The leaves are more than 1 meter long and about 10 centimeters wide, and the stem is about 3 centimeters thick and has a core.
コウリャンには子実型コウリャン(グレインソルガム)、ソルゴー型コウリャン(フォレッジソルガム)がある。子実型は、穀物を採取するのが目的で栽培されており、穀物を食料や酒の原料および飼料として用いられる。ソルゴー型は、穂はほとんどつかないが、茎および葉を丸ごと飼料として用いられる。 There are two types of culang: grain-type cuoliang (grain sorghum) and solgo-type cuoliang (forage sorghum). The grain type is cultivated for the purpose of collecting grains, and the grains are used as a raw material and feed for food and liquor. The Sorgo type has few ears, but the whole stem and leaves are used as feed.
本発明に適する品種としては、子実型コウリャンが本発明において2型糖尿病に顕著な改善効果を有することが判明したオクタコサナール及びトリアコンタナール成分をより多く含むため好適である。前記両成分の含有量は、コウリャン茎からのサンプル採取方法に大きく依存すること、ならびに前記両成分はとくに茎部の表皮部分に多く、さらには茎の節近傍の表皮部分に極めて高濃度で存在することから、採取の仕方によってはソルゴー型においても十分に本願の効果を発揮できることが確認されている。他方、茎部の袴及び葉の表面にも同様に白い粉状のワックスが吹いているが、前記ワックスにはオクタコサナール及びトリアコンタナールはほとんど含まれないことが我々の分析で明らかになっている。 As the varieties suitable for the present invention, grain-type cuolian is preferable because it contains more octacosanal and triacontananal components that have been found to have a significant improvement effect on type 2 diabetes in the present invention. The content of both components depends greatly on the sampling method from the cucumber stalk, and both the components are particularly present in the epidermis portion of the stem, and also present in extremely high concentrations in the epidermis portion near the stem nodes. Therefore, it has been confirmed that the effect of the present application can be sufficiently exerted even in the solgo type depending on the way of collection. On the other hand, white powdery wax is blown on the surface of the stem buds and leaves as well, but our analysis reveals that the wax is almost free of octacosanal and triacontanal. .
一方、本願において比較例に使用しているサトウキビは、イネ科サトウキビ属の植物でありカンショ(甘蔗)とも呼ばれ、テンサイと並んで砂糖(蔗糖)の原料となる。世界各地の熱帯、亜熱帯地域で広く栽培されており、主な産出国および生産量の割合は、ブラジル(28.0%)、インド(21.7%)、中国(6.4%)である。日本では、主に沖縄県と奄美群島を中心に栽培されている。 On the other hand, the sugarcane used in the comparative example in the present application is a plant belonging to the genus Sugaraceae and is also called sweet potato, and is a raw material for sugar (sucrose) along with sugar beet. Widely cultivated in tropical and subtropical regions around the world, the main producing countries and production ratios are Brazil (28.0%), India (21.7%) and China (6.4%). In Japan, it is cultivated mainly in Okinawa Prefecture and Amami Islands.
すなわち、コウリャンはイネ科モロコシ属に属し食用であるが、サトウキビはイネ科サトウキビ属に属し砂糖の原料であり、両者は全く属の異なる植物である。 In other words, Koryang belongs to the genus Sorghum and is edible, but sugarcane belongs to the genus Saccharomyces and is a raw material of sugar, and both are plants of completely different genera.
(2)本発明のワックス混合物の分離及び抽出方法
以下に本発明のワックス混合物の代表的な製造方法を挙げる。
(2) Separation and extraction method of the wax mixture of the present invention A typical production method of the wax mixture of the present invention is shown below.
表皮の分離方法
本発明のワックス混合物は、コウリャンの茎部の表皮部分、とくに節部の近傍に集中して高濃度に存在しているため、各種手段を用いて選択的かつ効率的に回収することが望ましい。例えば、ケインセパレーションシステム(以下、CSSと略記する。米国AmClyde社製、米国特許第3690358号、図2)等の分離装置により表皮のラインド部分と内部組織のピス(Pith)とを機械的に分離して、そのうちの表皮を抽出に供する方法、コウリャンの表皮をワイヤーブラシを用いて手作業で研磨して収集する方法、ナイフ、剃刀等により手作業によって削り取って収集する方法、あるいは自動皮むき機等を利用する方法が有効である。
Separation method of the epidermis The wax mixture of the present invention is concentrated and concentrated in the epidermis part of the sorghum stalk, particularly in the vicinity of the nodal part, so that it can be selectively and efficiently recovered using various means. It is desirable. For example, the lined portion of the epidermis and the pis of the internal tissue are mechanically separated by a separation device such as a cane separation system (hereinafter abbreviated as CSS; manufactured by AmClyde, US Pat. No. 3,690,358, FIG. 2). Then, the method of subjecting the skin to extraction, the method of collecting and collecting the wolfberry skin manually using a wire brush, the method of scraping and collecting by hand with a knife, razor, etc., or the automatic peeler Etc. are effective.
ワックス成分の抽出・精製方法
次に、ワックス成分は、採取した表皮部分からガラス製ソックスレー抽出器等を用いた溶剤抽出法によって得る。すなわち、溶剤は、ベンゼン、イソプロパノール、ヘキサンなどの有機溶媒を用いて、湯浴にて70〜100℃で、2〜4時間加温して抽出を行った後、残留溶剤を蒸発して乾固させて粗ワックスを得る。さらに、前記粗ワックスを薄膜蒸留器にて蒸留し、高沸点分を残渣として除去することにより、本発明の精製ワックス混合物を得る。
How extraction and purification of the wax component then wax component, obtained by solvent extraction using glass Soxhlet extractor or the like from the collected skin portion. That is, the organic solvent such as benzene, isopropanol and hexane was used for extraction by heating in a hot water bath at 70 to 100 ° C. for 2 to 4 hours, and then the residual solvent was evaporated to dryness. To obtain a crude wax. Further, the crude wax is distilled with a thin film distiller, and the high boiling point component is removed as a residue to obtain the purified wax mixture of the present invention.
(3)併用可能なワックス混合物以外の成分
本発明において併用可能なワックス混合物以外の成分としては、本発明の目的を妨げない限り特に制限はなく、目的に応じて適宜選択することができ、例えば、以下の薬効成分、添加剤などが挙げられる。前記薬効成分としては、例えば、ビタミン類、血圧降下剤、血管拡張剤、抗不整脈剤、血栓溶解剤、高脂血症用剤、などが挙げられる。前記添加剤としては、特に制限はなく、例えば、安定化剤、界面活性剤、可溶化剤、水溶性高分子、抗酸化剤、pH調整剤、分散剤などが挙げられる。
(3) Components other than the wax mixture that can be used in combination The components other than the wax mixture that can be used in the present invention are not particularly limited as long as they do not interfere with the purpose of the present invention, and can be appropriately selected according to the purpose. The following medicinal ingredients, additives and the like can be mentioned. Examples of the medicinal components include vitamins, blood pressure lowering agents, vasodilators, antiarrhythmic agents, thrombolytic agents, hyperlipidemia agents, and the like. The additive is not particularly limited, and examples thereof include a stabilizer, a surfactant, a solubilizer, a water-soluble polymer, an antioxidant, a pH adjuster, and a dispersant.
(4)本発明の改善剤の形状
本発明の2型糖尿病改善剤ならびに飲食品の剤形としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、粉末、細粒、顆粒、マイクロカプセルなどの固形剤としてもよく、更に、これらを錠剤、フィルムコート剤などとしてもよく、カプセルなどに充填してもよい。また、適宜選択した溶媒によって溶液化又は懸濁化して、液剤としてもよい。
(4) Shape of the improving agent of the present invention The type 2 diabetes improving agent of the present invention and the dosage form of food and drink are not particularly limited and can be appropriately selected according to the purpose. For example, powder, fine granules, It may be a solid agent such as a granule or a microcapsule, and may be a tablet or a film coat agent, or may be filled in a capsule. Moreover, it is good also as a solution by making into solution or suspending with the solvent selected suitably.
(5)本発明の飲食物
本発明のワックス混合物を含む2型糖尿病改善飲食物としては、これらのワックス混合物を配合した調理油、飲料類、錠剤、顆粒剤、ドレッシング類、マヨネーズ類、クリーム類、チョコレート、ポテトチップス等が挙げられる。このような飲食物は、本発明のワックス混合物の他に、飲食物の種類に応じて一般に用いられる食品原料を添加して製造することができる。
(5) Food and drink of the present invention Type 2 diabetes-improving food and drink containing the wax mixture of the present invention includes cooking oils, beverages, tablets, granules, dressings, mayonnaises and creams containing these wax mixtures. , Chocolate, potato chips and the like. Such foods and drinks can be produced by adding generally used food materials according to the types of foods and drinks in addition to the wax mixture of the present invention.
(6)本発明のワックス混合物の適正投与量
本発明の実施例において、約40g のマウスが0.5質量%のワックス混合物を配合した混合飼料を7g/日(ワックス混合物として0.035g)摂取した場合、2型糖尿病改善効果があることが見出された。一般的には、ラットやマウスでの体重1kgの有効量の約1/50がヒトでの適正用量であると言われる。したがって、ここでの摂取量は50kgのヒトに換算すると0.875g/日となる。
以下、実施例に基づいて本発明をさらに詳細に説明する。
(6) Appropriate dosage of the wax mixture of the present invention In the examples of the present invention, about 40 g of mice ingested 7 g / day (0.035 g as a wax mixture) of mixed feed containing 0.5% by weight of the wax mixture. , It has been found that there is an effect of improving type 2 diabetes. Generally, it is said that about 1/50 of the effective amount of 1 kg body weight in rats and mice is an appropriate dose in humans. Therefore, the intake here is 0.875 g / day when converted to a human of 50 kg.
Hereinafter, the present invention will be described in more detail based on examples.
[製造例1]
(1)コウリャン茎の表皮の採取
マウス試験に採用したコウリャンワックスの原料であるコウリャンの産地と品種及び表皮の採取方法は次の通りである。コウリャン原料として、沖縄県粟国島産のフォレッジソルガム(品種名:ビッグシュガーソルゴー)を用いて、前記CSSよって表皮とラインドと芯とに機械的に分離して、表皮を収集して以下の溶剤抽出に供した。なお、比較のためのサトウキビワックスについても前記の方法で同様に得た。
[Production Example 1]
(1) Collection of corn stalk epidermis The production area and varieties of cuolian, which is the raw material of colour wax used in the mouse test, and the method of collecting the epidermis are as follows. Forage sorghum (variety name: Big Sugar Sorgo) from Yasukuni-jima, Okinawa Prefecture, as the raw material for Kouliang, mechanically separated into the epidermis, lined and core by the CSS, the epidermis is collected, and the following solvent extraction It was used for. A sugarcane wax for comparison was also obtained in the same manner as described above.
(2)ワックス成分の抽出・分離
抽出には2L用ガラス製ソックスレー抽出器を使用した。表皮サンプル150g、溶媒としてヘキサンを用い、ソックスレー抽出した。湯浴温度を90℃として、3時間抽出した後、残留溶剤を蒸発して乾固させて約100gの粗ワックスを得た。次に、前記粗ワックスを薄膜蒸留器にて蒸留して、高沸点分を残渣として除去することにより70gの精製ワックス混合物を得た。
(2) Extraction and Separation of Wax Component A 2 L glass Soxhlet extractor was used for extraction. A Soxhlet extraction was performed using 150 g of a skin sample and hexane as a solvent. After extraction for 3 hours at a hot water bath temperature of 90 ° C., the residual solvent was evaporated to dryness to obtain about 100 g of crude wax. Next, the crude wax was distilled with a thin film distiller to remove a high boiling point residue as a residue, thereby obtaining 70 g of a purified wax mixture.
(3)ワックス成分の分析
前記ワックス混合物の組成は、下記の条件にてガスクロマトグラフィーを行い、表1の結果を得た。
(3) Analysis of wax component The composition of the wax mixture was subjected to gas chromatography under the following conditions, and the results shown in Table 1 were obtained.
ガスクロマトグラフィー条件
カラム:DB−5((5%-Phenyl)-Methylpolysiloxane、カラム長:30m、
ID:0.25mm、膜厚:0.25μm、J&Wサイエンティフィック社製)
昇温条件:150℃→(4℃/分)→320℃(10分)
カラム流量:1.70mL/分
検出器:FID、検出器温度:350℃
キャリアーガス:N2
Gas chromatography condition column: DB-5 ((5% -Phenyl) -Methylpolysiloxane, column length: 30 m,
(ID: 0.25 mm, film thickness: 0.25 μm, manufactured by J & W Scientific)
Temperature rising condition: 150 ° C. → (4 ° C./min)→320° C. (10 min)
Column flow rate: 1.70 mL / min Detector: FID, Detector temperature: 350 ° C.
Carrier gas: N 2
表1より、由来原料のコウリャンにおいては、サトウキビに比べて本発明で着目しているオクタコサナール(C28)とトリアコンタナール(C30)を合計した高級飽和脂肪族アルデヒド成分が多く、とくにトリアコンタナール(C30)の含有量が顕著に多いことが特徴であることに対して、サトウキビにおいてはとくにオクタコサノール(C28)は多いが、高級飽和脂肪族アルデヒド成分が相対的に少ないことが分かる。 According to Table 1, in the raw material cuolian, there are many higher saturated aliphatic aldehyde components that are the sum of octacosanal (C28) and triacontanal (C30), which are the focus of the present invention, compared with sugarcane. It can be seen that the content of C30) is remarkably high, whereas in sugarcane, especially octacosanol (C28) is high, but the higher saturated aliphatic aldehyde component is relatively low.
[マウス試験条件]
・試験マウスの種類;雄性、4週齢(「KK−Ay/Ta」、日本クレア(株))、2型糖尿病モデルマウス)を使用した。
・1群のマウス数;6匹
・飼育方法;1週間のAIN−93G標準飼料で予備飼育後、下記の実施例1および比較例1の各ワックス配合系試験飼料を投与して8週間飼育した。
・飼育環境;飼育中、試験飼料、水は自由摂食とし、室温20〜25℃、12時間の明暗サイクルで、プラスチックケージ内に一匹ずつ隔離飼育した。
・AIN−93G基本飼料の配合組成(単位:質量%);カゼイン20、コーンスターチ39.8、α化コーンスターチ13.2、シュークロース10.0、大豆油7.0、セルロースパウダー5.0、AIN−93Gミネラル混合3.5、AIN−93Gビタミン混合1.0
・標準飼料;上記の基本飼料に、オリーブ油を0.5添加
・試験飼料;上記の基本飼料に、ワックス混合物を各々0.5添加
[Mouse test conditions]
Test mouse type: male, 4 weeks old (“KK-Ay / Ta”, Nippon Claire Co., Ltd., type 2 diabetes model mouse) was used.
-Number of mice per group: 6-Breeding method: After pre-breeding with AIN-93G standard feed for 1 week, each test compound containing the waxes of Example 1 and Comparative Example 1 described below was administered and reared for 8 weeks. .
-Breeding environment: During the breeding period, the test feed and water were freely fed, and the animals were isolated and housed individually in plastic cages at a room temperature of 20 to 25 ° C and a 12 hour light / dark cycle.
-Composition of AIN-93G basic feed (unit: mass%):
・ Standard feed: Add 0.5% olive oil to the above basic feed ・ Test feed: Add 0.5% each of the wax mixture to the above basic feed
[実施例1]
(コウリャンワックス配合系試験飼料)(本発明)
製造例1により得られた精製ワックス混合物を用いて、飼育試験を行った。
試験飼料は、予め基本飼料に使用する大豆油に固形状のコウリャンワックスを均一に溶解した後、AIN−93G基本飼料 99.5質量%、コウリャンワックス0.5質量%となるように、均一に混合して用意したものを試験食飼料として、前記の条件下で飼育した。
[Example 1]
(Korean wax-containing test feed) (present invention)
A breeding test was conducted using the purified wax mixture obtained in Production Example 1.
The test feed should be uniformly dissolved in soybean oil used in the basic feed in advance, so that the solid Koulian wax is uniformly dissolved, and then 99.5% by weight of the AIN-93G basic feed and 0.5% by weight of the Kourian wax. What was prepared by mixing was reared under the above conditions as a test diet.
[比較例1]
(サトウキビワックス配合系試験飼料)
試験飼料は、予め基本飼料に使用する大豆油に固形状のサトウキビワックスを均一に溶解した後、AIN−93G基本飼料 99.5質量%、サトウキビワックス0.5質量%となるように、均一に混合して用意したものを試験食として、前記の条件下で飼育した。2型糖尿病モデルマウスに対するコウリャンワックスおよびサトウキビワックスの投与の血糖値ならびに空腹時血漿中のインスリン濃度に及ぼす影響を表2に示す。
[Comparative Example 1]
(Sugar cane wax combination system test feed)
The test feed was prepared by uniformly dissolving the solid sugarcane wax in soybean oil used in the basic feed in advance, and then uniformly in such a way that the AIN-93G basic feed was 99.5% by mass and the sugarcane wax was 0.5% by mass. What was prepared by mixing was reared under the above conditions as a test meal. Table 2 shows the effect of administration of cucumber wax and sugarcane wax on type 2 diabetes model mice on blood glucose levels and insulin concentrations in fasting plasma.
表2から、2型糖尿病モデルマウスにワックス配合系試験飼料を投与すると、サトウキビワックス配合系試験飼料に比べて、本発明のコウリャンワックス配合系試験飼料マウスにおける血糖値、インスリン濃度が大幅に低下している。また、図1に示すように、コントロール(標準飼料系)に比べて、サトウキビワックス配合系での空腹時血漿インスリン濃度は改善が認められないのに対して、コウリャンワックス配合系でのそれは約50%減と大幅な改善効果が認められている。 From Table 2, administration of a wax-containing test feed to type 2 diabetes model mice significantly reduced the blood glucose level and insulin concentration in the cucumber wax-containing test feed mouse of the present invention compared to the sugar cane wax-containing test feed. ing. Moreover, as shown in FIG. 1, compared with the control (standard feed system), the fasting plasma insulin concentration in the sugar cane wax compounded system is not improved, whereas that in the cucumber wax compounded system is about 50%. % Reduction and a significant improvement effect are recognized.
[製造例2]
次に、本発明の特徴である、オクタコサナールとトリアコンタナールが2型糖尿病改善剤として有効であることを証明するために、ワックスの還元処理を行った場合と、還元処理を行わない場合との比較試験を行った。
[Production Example 2]
Next, in order to prove that octacosanal and triacontanal, which are the characteristics of the present invention, are effective as a type 2 diabetes mellitus-improving agent, a case where wax reduction treatment is performed and a case where reduction treatment is not performed A comparative test was conducted.
(1)コウリャン茎の表皮の採取
コウリャン原料として、中国遼寧省黒山県産のコウリャンの茎(品種名:瀋雑5号 通称6A)を用いた。まず、コウリャン茎部の表皮部分のみを剃刀あるいはピーラーで削り落して収集して、以下の溶剤抽出に供した。
(1) Collection of the skin of the cucumber stalk The cucumber stalk (variety name: Jongno 5 No. 6A) from Kuroyama Prefecture, Liaoning Province, China was used as the cucumber raw material. First, only the epidermis part of the sorghum stalk was scraped off and collected with a razor or a peeler and subjected to the following solvent extraction.
(2)ワックス成分の抽出・分離
抽出には2L用ガラス製ソックスレー抽出器を使用した。表皮サンプル150g、溶媒としてヘキサンを用い、ソックスレー抽出した。湯浴温度を90℃として、3時間抽出した後、残留溶剤を蒸発して乾固させて約100gの粗ワックスを得た。次に、前記粗ワックスを薄膜蒸留器にて蒸留して、高沸点分を残渣として除去することにより70gの精製ワックス混合物(以下、「非還元処理コウリャンワックス」という。)を得た。
(2) Extraction and Separation of Wax Component A 2 L glass Soxhlet extractor was used for extraction. A Soxhlet extraction was performed using 150 g of a skin sample and hexane as a solvent. After extraction for 3 hours at a hot water bath temperature of 90 ° C., the residual solvent was evaporated to dryness to obtain about 100 g of crude wax. Next, the crude wax was distilled with a thin-film distiller to remove a high-boiling portion as a residue, thereby obtaining 70 g of a purified wax mixture (hereinafter referred to as “non-reduced coconut wax”).
(3)ワックスの還元処理
前記の非還元処理コウリャンワックスを以下の反応条件で還元処理を行って、還元処理コウリャンワックス(以下、「還元処理コウリャンワックス」という。)を得た。
(3) Reduction treatment of wax The above-mentioned non-reduction treated sorghum wax was subjected to a reduction treatment under the following reaction conditions to obtain a reduced sorghum wax (hereinafter referred to as “reduced sorghum wax”).
<還元処理条件>
反応:クロロホルム250mLと非還元処理コウリャンワックス10gを還流管付き2リットル丸底フラスコに入れ、60℃の湯浴で加熱溶解する。溶解した後、イソプロバノール250mLを添加し、軽く振とうする。あらかじめ0.1N NaOH水溶液125mLにNaBH4粉末25gを溶解したNaBH4溶液を調整しておき、これを上記ワックス溶液のフラスコに添加し、よく振とうし、60℃湯浴で2時間放置する。
反応終了:1リットル分液ロ斗で下層を取り、上層を捨てる。下層をフラスコに戻し、60℃に加熱したイオン交換水500mLを加え、よく振とうする。再度分液ロ斗で下層を取り、上層を捨てる。下層を加熱濃縮した後、真空乾燥器で蒸発乾固させて反応物を得た。収率85%。
精製:薄膜蒸留器で、270℃、0.2mmHgで蒸留し、留分を得た。収率59%。
<Reduction treatment conditions>
Reaction: 250 mL of chloroform and 10 g of non-reduced coconut wax are placed in a 2 liter round bottom flask equipped with a reflux tube and dissolved by heating in a 60 ° C. hot water bath. After dissolution, add 250 mL isopropanol and shake gently. A NaBH 4 solution in which 25 g of NaBH 4 powder is dissolved in 125 mL of 0.1N NaOH aqueous solution is prepared in advance, and this is added to the flask of the wax solution, shaken well, and left in a 60 ° C. hot water bath for 2 hours.
End of reaction: Take the lower layer with a 1 liter separatory funnel and discard the upper layer. Return the lower layer to the flask, add 500 mL of ion-exchanged water heated to 60 ° C., and shake well. Take the lower layer again with a separatory funnel and discard the upper layer. The lower layer was concentrated by heating, and then evaporated to dryness in a vacuum dryer to obtain a reaction product. Yield 85%.
Purification: Distillation was performed with a thin-film distiller at 270 ° C. and 0.2 mmHg. Yield 59%.
(4)ワックス成分の分析
前記の非還元処理コウリャンワックスおよび還元処理コウリャンワックスの各ワックス混合物の組成は、下記の条件にてガスクロマトグラフィーにて測定を行い、表3の結果を得た。
(4) Analysis of Wax Component The composition of each wax mixture of the non-reduced sorghum wax and the reduced sorghum wax was measured by gas chromatography under the following conditions, and the results shown in Table 3 were obtained.
ガスクロマトグラフィー条件
カラム:DB−5((5%-Phenyl)-Methylpolysiloxane、カラム長:30m、
ID:0.25mm、膜厚:0.25μm、J&Wサイエンティフィック社製)
昇温条件:150℃→(4℃/分)→320℃(10分)
カラム流量:1.70mL/分
検出器:FID、検出器温度:350℃
キャリアーガス:N2
Gas chromatography condition column: DB-5 ((5% -Phenyl) -Methylpolysiloxane, column length: 30 m,
(ID: 0.25 mm, film thickness: 0.25 μm, manufactured by J & W Scientific)
Temperature rising condition: 150 ° C. → (4 ° C./min)→320° C. (10 min)
Column flow rate: 1.70 mL / min Detector: FID, Detector temperature: 350 ° C.
Carrier gas: N 2
表3より、非還元処理コウリャンワックスにおいては、本発明で着目している高級飽和脂肪族アルデヒドの中でとくに、オクタコサナール(C28)とトリアコンタナール(C30)の含有量が他の高級飽和脂肪族アルデヒド成分や高級飽和脂肪族アルコール成分に比較して顕著に多いのに対して、還元処理コウリャンワックスにおいては、オクタコサナール(C28)とトリアコンタナール(C30)の両成分が共に大幅に減少しており、同時に高級飽和脂肪族アルコールのオクタコサノール(C28)とトリアコンタノール(C30)の含有量が大幅に増加していることが分かる。 From Table 3, in the non-reduced sorghum wax, among the higher saturated aliphatic aldehydes of interest in the present invention, the contents of octacosanal (C28) and triacontanal (C30) are particularly high. In contrast to the aldehyde component and higher saturated fatty alcohol component, both the components of octacosanal (C28) and triacontanal (C30) are significantly reduced in the reduced coconut wax. At the same time, it can be seen that the contents of the higher saturated aliphatic alcohols octacosanol (C28) and triacontanol (C30) are greatly increased.
[マウス試験条件]
・試験マウスの種類;雄性、4週齢(「KK−Ay/Ta」、日本クレア(株))、2型糖尿病モデルマウス)を使用した。
・1群のマウス数;8匹
・飼育方法;1週間のAIN−93G標準飼料で予備飼育後、下記の実施例2および比較例2の各ワックス配合系試験飼料を投与して8週間飼育した。
・飼育環境;飼育中、試験飼料、水は自由摂食とし、室温20〜25 ℃ 、12時間の明暗サイクルで、プラスチックケージ内に一匹ずつ隔離飼育した。
・AIN−93G基本飼料の配合組成(単位:質量%);カゼイン20、コーンスターチ39.8、α化コーンスターチ13.2、シュークロース10.0 、大豆油7.0、セルロースパウダー5.0、AIN−93Gミネラル混合3.5、AIN−93Gビタミン混合1.0
・標準飼料;上記の基本飼料に、オリーブ油を0.5添加
・試験飼料;上記の基本飼料に、ワックス混合物を各々0.5添加
[Mouse test conditions]
Test mouse type: male, 4 weeks old (“KK-Ay / Ta”, Nippon Claire Co., Ltd., type 2 diabetes model mouse) was used.
-Number of mice per group: 8-Breeding method: After pre-breeding with AIN-93G standard feed for 1 week, each of the wax-mixed test feeds of Example 2 and Comparative Example 2 below was administered and kept for 8 weeks. .
-Breeding environment: During the breeding period, the test feed and water were freely fed, and the animals were isolated and kept individually in plastic cages at a room temperature of 20 to 25 ° C and a 12 hour light / dark cycle.
-Composition of AIN-93G basic feed (unit: mass%):
・ Standard feed: Add 0.5% olive oil to the above basic feed ・ Test feed: Add 0.5% each of the wax mixture to the above basic feed
[実施例2]
(非還元処理コウリャンワックス配合系試験飼料)(本発明)
前記製造例1の非還元処理コウリャンワックスを用いて、飼育試験を行った。
試験飼料は、予め基本飼料に使用する大豆油に固形状の非還元処理コウリャンワックスを均一に溶解した後、AIN−93G基本飼料 99.5質量%、非還元処理コウリャンワックス0.5質量%となるように、均一に混合して用意したものを試験食飼料として、前記の条件下で飼育した。
[Example 2]
(Non-reduced cucumber wax-containing test feed) (Invention)
A breeding test was performed using the non-reducing treated sorghum wax of Production Example 1.
The test feed was prepared by uniformly dissolving solid non-reduced cucumber wax in soybean oil used in advance for the basic feed, and then AIN-93G basic feed 99.5% by mass, non-reduced cucumber wax 0.5% by mass In this way, the mixture prepared by uniformly mixing was reared under the above conditions as a test diet.
[比較例2]
(還元処理コウリャンワックス配合系試験飼料)
前記製造例2の還元処理コウリャンワックスを用いて、飼育試験を行った。
試験飼料は、予め基本飼料に使用する大豆油に固形状の還元処理コウリャンワックスを均一に溶解した後、AIN−93G基本飼料 99.5質量%、還元処理コウリャンワックス0.5質量%となるように、均一に混合して用意したものを試験食として、前記の条件下で飼育した。
[Comparative Example 2]
(Reduction-treated cucumber wax compounded test feed)
A breeding test was conducted using the reduction-treated kuryan wax of Production Example 2.
The test feed is prepared by uniformly dissolving the solid reduced cucumber wax in soybean oil used in advance for the basic feed, and then AIN-93G basic feed 99.5% by mass and reduced cucumber wax 0.5% by mass. In addition, a sample prepared by mixing uniformly was bred under the above conditions as a test food.
飼育終了後、エーテル麻酔下でマウスから約1mL採血した。約1mLを3000rpmで10分間遠心分離し、上清を血清サンプルとし、インスリン、アディポネクチンおよびレジスチンの各濃度の測定に用いた。
・インスリン濃度:モリナガ超高感度マウスインスリン測定キット( 株式会社森永生命科学研究所製)
・アディポネクチン濃度: QuantikineAdiponectin/Acrp30 Immunoassayキット(R&D SYSTEMS製)
・レジスチン濃度:Resistin, ELISA Kit,Quantikine (R&D SYSTEM製)
After the breeding, about 1 mL of blood was collected from the mouse under ether anesthesia. About 1 mL was centrifuged at 3000 rpm for 10 minutes, and the supernatant was used as a serum sample, which was used for measurement of each concentration of insulin, adiponectin and resistin.
・ Insulin concentration: Morinaga ultrasensitive mouse insulin measurement kit (manufactured by Morinaga Life Science Institute)
・ Adiponectin concentration: QuantikineAdiponectin / Acrp30 Immunoassay kit (R & D SYSTEMS)
-Resistin concentration: Resistin, ELISA Kit, Quantikine (R & D SYSTEM)
非還元処理コウリャンワックスおよび還元処理コウリャンワックスの投与の血糖値、空腹時血漿中のインスリン、アディポネクチンおよびレジスチンの各濃度に及ぼす影響を表4に示す。 Table 4 shows the effects of administration of non-reduced cucumber wax and reduced cucumber wax on blood glucose levels, fasting plasma insulin, adiponectin and resistin concentrations.
表4から、2型糖尿病モデルマウスにコウリャンワックス配合系試験飼料を投与すると、還元処理コウリャンワックス配合系に比べて本発明の非還元処理コウリャンワックス配合系試験飼料を用いたマウスにおける血糖値およびインスリン濃度が低下し、アディポネクチン濃度が増加している。一方、インスリン抵抗性を引き起こすとされるアディポサイトカインの一種であるレジスチン濃度が、還元処理コウリャンワックス配合系に比べて本発明の非還元処理コウリャンワックス配合系試験飼料を用いたマウスにおいて大幅に低下している。 From Table 4, blood glucose level and insulin in mice using the non-reduced cucurian wax compounded test diet of the present invention compared to the reduced treated cucurian wax compounded system when the type 2 diabetes model mouse was administered with the cucurian wax compounded test diet The concentration is decreasing and the adiponectin concentration is increasing. On the other hand, the resistin concentration, which is a kind of adipocytokine that is believed to cause insulin resistance, is significantly lower in mice using the non-reduced cucumber wax-blended test feed of the present invention than in the reduced-treated cucumber wax-blended system. ing.
すなわち、オクタコサナール(C28)とトリアコンタナール(C30)が2型糖尿病の改善に有効であることが分かった。 That is, it was found that octacosanal (C28) and triacontanal (C30) are effective in improving type 2 diabetes.
[実施例3]
年齢70歳男性を被験者とし、ヒト介入試験を行った。検査前日は過度な運動を避け、食事はSB食品の冷凍食品「貝柱雑炊」、「かに雑炊」及び「とり雑炊」のいずれも一食(180〜210kcal)を朝・昼・晩とし、飲酒はせず、19時以降は絶食とした。
[Example 3]
A human intervention test was conducted with a 70-year-old male as a test subject. The day before the inspection, avoid excessive exercise, and drink SB food frozen foods “Scallop miscellaneous cooking”, “Kani miscellaneous cooking” and “Tori miscellaneous cooking” with one meal (180-210 kcal) in the morning, noon, and evening It was not fast, and it was fasted after 19:00.
前日から12時間の絶食後、30ccの牛乳に非還元処理コウリャンワックス30mgを入れ、分散して飲んだ。その30分後に空腹時の血糖値を自己検査用血糖値測定器(アークレイ(株)グルコカードメーターセット)を用いて測定した。 After fasting for 12 hours from the previous day, 30 mg of non-reduced mulberry wax was added to 30 cc of milk and dispersed and drunk. Thirty minutes later, the fasting blood glucose level was measured using a blood glucose level measuring device for self-test (ARKRAY Co., Ltd. gluco card meter set).
その直後、ブドウ糖14gを水100ccとともに摂取した。摂取開始から、30、60、120、150、180及び210分後と経時的に自己血糖測定を行った。 Immediately thereafter, 14 g of glucose was ingested with 100 cc of water. Autologous blood glucose was measured over time from 30, 60, 120, 150, 180 and 210 minutes after the start of ingestion.
[比較例3]
別の日に、非還元処理コウリャンワックスを服用しない以外は、実施例と同様に自己血糖測定を行った。
[Comparative Example 3]
On another day, self blood glucose measurement was performed in the same manner as in the example except that the non-reduced sorghum wax was not taken.
実施例3と比較例3のそれぞれの血糖値をグラフにしたものを図2に示す。図2より、非還元処理コウリャンワックスを服用した方が、血糖値の上昇が小さいことが明瞭に認められた。 FIG. 2 shows a graph of the blood glucose levels of Example 3 and Comparative Example 3. From FIG. 2, it was clearly recognized that the increase in blood glucose level was smaller when the non-reduced sorghum wax was taken.
以上の実施例ならびに比較例の結果から、オクタコサナール及びトリアコンタナールの高級飽和脂肪族アルデヒドを主成分とする本発明のコウリャンワックス混合物は、インスリン非依存性の2型糖尿病を極めて効果的に改善できることがわかった。 From the results of the above Examples and Comparative Examples, the quorian wax mixture of the present invention mainly composed of higher saturated aliphatic aldehydes of octacosanal and triacontanar can extremely effectively improve insulin-independent type 2 diabetes. I understood.
本発明によると、低コストで容易に製造でき、生活習慣病に起因する2型糖尿病の改善に有効であり、安全性が高く常用可能なコウリャン由来の特定組成のワックス混合物を有効成分とする2型糖尿病改善剤、及び、それを含み、病院用飲食品、健康飲料乃至食品、飼料用サプリメント等として好適な飲食物を提供することができる。 According to the present invention, a wax mixture having a specific composition derived from Koryan, which can be easily produced at low cost, is effective in improving type 2 diabetes caused by lifestyle-related diseases, and is highly safe and can be used, is used as an active ingredient. Type-diabetes-improving agent, and foods and drinks suitable for them as hospital foods and drinks, health drinks or foods, feed supplements and the like can be provided.
Claims (4)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010189716A JP5586381B2 (en) | 2009-10-07 | 2010-08-26 | Type 2 diabetes-improving agent and food and drink containing the same |
PCT/JP2010/067021 WO2011043237A1 (en) | 2009-10-07 | 2010-09-30 | Agent for ameliorating type-2 diabetes, and food or beverage containing same |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009233649 | 2009-10-07 | ||
JP2009233649 | 2009-10-07 | ||
JP2010089463 | 2010-04-08 | ||
JP2010089463 | 2010-04-08 | ||
JP2010189716A JP5586381B2 (en) | 2009-10-07 | 2010-08-26 | Type 2 diabetes-improving agent and food and drink containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011231095A true JP2011231095A (en) | 2011-11-17 |
JP5586381B2 JP5586381B2 (en) | 2014-09-10 |
Family
ID=43856695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010189716A Expired - Fee Related JP5586381B2 (en) | 2009-10-07 | 2010-08-26 | Type 2 diabetes-improving agent and food and drink containing the same |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5586381B2 (en) |
WO (1) | WO2011043237A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021040514A (en) * | 2019-09-10 | 2021-03-18 | 日油株式会社 | Glyceraldehyde metabolism promoter |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8722093B2 (en) | 2009-02-23 | 2014-05-13 | NanoRx, Inc. | Policosanol nanoparticles |
US9034383B2 (en) | 2010-08-23 | 2015-05-19 | NanoRx, Inc. | Policosanol nanoparticles |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001299204A (en) * | 2000-04-26 | 2001-10-30 | Toyo Shinyaku:Kk | Method for producing green plant powder |
-
2010
- 2010-08-26 JP JP2010189716A patent/JP5586381B2/en not_active Expired - Fee Related
- 2010-09-30 WO PCT/JP2010/067021 patent/WO2011043237A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001299204A (en) * | 2000-04-26 | 2001-10-30 | Toyo Shinyaku:Kk | Method for producing green plant powder |
Non-Patent Citations (1)
Title |
---|
JPN6010064931; K. Butchi Lakshmi,et al: 'Hypoglycemic effect of selected sorghum recipes' Nutrition Research Volume 16, Issue 10, 1996, Pages 1651-1658 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021040514A (en) * | 2019-09-10 | 2021-03-18 | 日油株式会社 | Glyceraldehyde metabolism promoter |
JP7342545B2 (en) | 2019-09-10 | 2023-09-12 | 日油株式会社 | Glyceraldehyde metabolism enhancer |
Also Published As
Publication number | Publication date |
---|---|
JP5586381B2 (en) | 2014-09-10 |
WO2011043237A1 (en) | 2011-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1243559C (en) | Herbal composition and medicament against diabetes mellitus type II manufactured thereof | |
JP6381818B2 (en) | Composition comprising an extract or fraction of a genus Fox | |
JP5586381B2 (en) | Type 2 diabetes-improving agent and food and drink containing the same | |
CN111602809A (en) | Instant braised polygonatum odoratum food and preparation method thereof | |
CN110624042B (en) | Composition for treating diabetic diseases | |
KR20080018676A (en) | Anti-diabetic food composition comprising extracts from natural herbal materials and propolis and process for preparing the same | |
US10799547B2 (en) | Composition comprising suaeda japonica for preventing or alleviating diabetes | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
CN107136512A (en) | A kind of vinegar capsule of auxiliary hyperglycemic reducing blood lipid and preparation method thereof | |
JP3628999B2 (en) | Anonymous tea and its manufacturing method | |
CN104758309B (en) | The purposes of raspberry polysaccharide for reducing blood sugar | |
JP2013063956A (en) | Glp-1 secretion promoter | |
KR101938056B1 (en) | A composition for treating, improving and preventing of diabetes mellitus comprising Gracilariopsis chorda ohmi extract or Gracilariopsis chorda ohmi fraction | |
JP2005336069A (en) | Antidiabetic composition | |
KR102668450B1 (en) | Hangover reliever comprising Codium extract or fraction thereof as an active ingredient | |
JP3616950B2 (en) | Nutritional composition derived from citrus | |
JP2005089419A (en) | Garlic extract | |
TWI784169B (en) | Prevention or improvement agent for nocturnal frequent urination | |
KR20140032961A (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
JP2013053107A (en) | Agent for inhibiting blood pressure elevation and food and drink containing the same | |
JPH1149690A (en) | Composition for stimulating lipolysis | |
KR20100111088A (en) | Composition for preventing and treating diabetes mellitus or diabetic complications comprising extract of herbal combination | |
CN112603978A (en) | Traditional Chinese medicine composition for treating type 2 diabetes combined with coronary heart disease and preparation method thereof | |
JP2008214246A (en) | Age production inhibitor and method for producing the same | |
JP2014155489A (en) | Composition for preventing and treating diabetes, containing smilax china l. leaves extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130410 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140507 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140602 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140624 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140722 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5586381 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |